FDA Approves First Drug to Prevent Graft Versus Host Disease
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 21 - Project Orbis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Project Orbis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Project Orbis Today - Breaking & Trending Today
AstraZeneca: NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES POSITIVE RECOMMENDATION FOR TAGRISSO ? (osimertinib) IN ENGLAND FOR PATIENTS WITH EARLY-STAGE LUNG CANCER
Osimertinib will be made available via the Cancer Drugs Fund (CDF) to patients in England with completely resected early-stage IB-IIIA EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).1
Source: finanznachrichten.de
FDA OKs Adjuvant Atezolizumab for Early-Stage Lung Cancer
The drug is now also approved for adjuvant treatment following resection and platinum-based chemotherapy in early stage, non-small cell lung cancer with PD-L1 ≥ 1%.
Source: medscape.com
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
(1) Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma TOKYO and KENILWORTH, N.J., July 23, 2...
Source: finanznachrichten.de
U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) ACCESSWIRE 17 Jul 2021, 04:31 GMT+10 - REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCESSWIRE / July 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved REZUROCK ™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients...
Source: saltlakecitysun.com